Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company ’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
V116 Designed to Target Serotypes that Account for 85% of all Invasive Pneumococcal Disease in Individuals Aged 65 and Over in the United States as of 20191
Phase 3 Clinical Trials for V116 to be Initiated in 2022
KENILWORTH, N.J.--(BUSINESS... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 14, 2022 Category: Pharmaceuticals Source Type: clinical trials
Merck and Ridgeback to Present Data Demonstrating That Treatment With Lagevrio (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Additional Exploratory Patient Subgroup and Virology Data from MOVe-OUT Presented at ECCMID
Among Patients With Infectious Virus at Baseline, No Patients Who Received Lagevrio Had Infectious Virus at Days 3, 5 or 10
KENILWORTH, N.J.&... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 1, 2022 Category: Pharmaceuticals Source Type: clinical trials
Lynparza (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced additional positive results from the Phase 3 OlympiA trial. In OlympiA, Lynparza demonstrated a statistically... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 17, 2022 Category: Pharmaceuticals Source Type: clinical trials
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Conditions: Tumor; Adenocarcinoma Interventions: Drug: Pembrolizumab; Drug: lenvatinib Sponsors: M.D. Anderson Cancer Center; STRATEGIC ALLIANCE: Merck Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 10, 2022 Category: Research Source Type: clinical trials
DDI Study of Evobrutinib and Carbamazepine
Condition: Healthy Interventions: Drug: Evobrutinib; Drug: Carbamazepine Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2022 Category: Research Source Type: clinical trials
